Comparative Pharmacology
Head-to-head clinical analysis: COREG CR versus CORGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG CR versus CORGARD.
COREG CR vs CORGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta1- and beta2-adrenergic receptors, leading to decreased heart rate, myocardial contractility, and blood pressure. Also prolongs sinoatrial node refractory period and inhibits renin release.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
40 mg orally once daily for hypertension; initial dose 40 mg once daily for angina, titrate up to 80-240 mg once daily. Maximum dose 320 mg/day.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Terminal elimination half-life: 20-24 hours (may extend to 40 hours in renal impairment). Clinical context: Allows once-daily dosing; steady-state achieved in 5-7 days.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Renal (unchanged, ~85-90%); fecal (<5%); biliary (<2%).
Category C
Category C
Beta-Blocker
Beta-Blocker